Physician profile
Patrick S Eye
NPI 1497768337
$1,176.63
in general payments reported to CMS, 2019-2025
14 companies · $563 in 2025
The $563 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.14 · 2023: $252 · 2024: $348 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $436.60 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $236.07 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $223.13 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $57.76 | 2024-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $53.10 | 2025 | Closurefast |
| Pfizer INC. | $32.19 | 2025 | |
| Astellas Pharma US INC | $23.46 | 2025 | Veozah |
| Lundbeck LLC | $19.38 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $18.51 | 2025 | |
| Abbott Laboratories | $18.00 | 2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $16.34 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $15.10 | 2024 | Eliquis |
| Hologic Sales and Service, LLC | $14.28 | 2025 | Novasure |
| Glaxosmithkline, LLC. | $12.71 | 2023 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Eye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.